Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Kyowa Kirin Nets 50%-Plus Sales from Overseas in 2021, Crysvita as Major Driver
Kyowa Kirin derived more than 50% of its consolidated revenue from overseas markets in 2021, with its earnings driven by growth of the X-linked hypophosphatemia (XLH) treatment Crysvita (burosumab), the company said on February 7. “Three global strategic products achieved…
To read the full story
Related Article
- Kyowa Kirin’s Revenue Up 11.7% in January-September on Bullish Global Portfolio
November 7, 2022
- Kyowa Kirin’s Q1 Sales Up 8.2% on Robust Overseas Performance Driven by Crysvita
May 11, 2022
- Kyowa Kirin’s January-September Sales Up 8.5% on Buoyant Global Products
November 2, 2021
- Kyowa Kirin’s H1 Sales Grow 4.6% on Brisk Global Products
August 4, 2021
- Kyowa Kirin’s Q1 Sales Rise on Strong Performance Overseas
May 10, 2021
BUSINESS
- Limited Sites, Bed Capacity Seen as Key Hurdles to Radioligand Therapy Uptake: Urologist
December 8, 2025
- Retevmo Now Available in Tablet Form: Lilly Japan
December 8, 2025
- Japan Ethical Drug Sales Rise 5.9% in October: Crecon
December 8, 2025
- Takeda Closes Innovent Oncology Deal, Bags Rights to 2 Late-Stage Assets
December 8, 2025
- Santen to Market Bayer’s Eylea Bio-AG; Launch Date Still Undisclosed
December 8, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…